Section 1332 of the Patient Protection and Affordable Care Act (PPACA) State Innovation Waivers – Reinsurance Waiver Quarterly Report

Reporting Instructions: Use the following template to capture data for quarterly 1332 waiver grant reporting, as specified in 45 CFR 155.1324(a), and referenced in your grant specific terms and conditions (STC). Quarterly reports are due 60 days following the end of each calendar quarter.

STATE: Maine									
A. GRANTEE INFORMATION									
1. Reporting Perio	d End Date		2. Report Due Date						
03/31/2021			05/31/2021						
3. 1st Quarterly Report	2nd Quarterly Report	3rd Quarterly Report	4. Federal Agency and Organization Element to Which Report is Submitted Consumer Information & Insurance Oversight (CCIIO)						
5. Federal Grant Number Assigned by Federal Agency		6a. DUNS Number		6b. EIN					
1 SIWIW190005-	01-00	160208815		016000001					
7. Recipient Organ State of Maine -		d Access Reinsurand	ce Association						
Address Line 1 254 Commercial	Street								
Address Line 2									
Address Line 3									
City		State		Zip Code					
Portland		ME		04101					
Zip Extension		8. Grant Period Start Date							
		Jan 1, 2019							
9. Grant Period Er	nd Date								
Dec 31, 2023									
10. Other Attachn	nents (attach other	documents as neede	ed or as instructed b	y the awarding Federal agency)					
MGARA Q1 Financ	ial Report								

Section 1332 of the Patient Protection and Affordable Care Act (PPACA) State Innovation Waivers – Reinsurance Waiver Quarterly Report

B. REPORT CERTIFICATION

11. Certification: I certify to the best of my knowledge and belief that this report is correct and complete for performance of activities for the purposes set forth in the award documents.

11a. Typed or printed name and title of Authorized Certifying Official

11b. Signature of Authorized Certifying Official

Christopher E. Howard Secretary, General Counsel Authorized Organizational Representative

11c. Telephone (area code, number, and extension)

(207) 791-1335

11d. E-mail address choward@pierceatwood.com

11e. Date report submitted (month/day/year)

May 25, 2021

C. PROGRESS OF SECTION 1332 WAIVER - General

12. Provide an update on progress made in implementing and/or operating the approved 1332 waiver. For the 3 months ended 3/31/21, total income was \$9,392,207, consisting entirely of premium collected on ceded policies. No assessment revenue or 1332 grant revenue was received in Q1. Gain on investments and interest income totaled -\$20,215 due to market conditions in Q1. Claims incurred for the period totaled \$13,570,026, which together with operational expenses resulted in total expense of \$ \$13,896,517. Claims are slightly ahead of year-ago levels but consistent with budget. The MGARA monthly operations report March 2021 is attached for reference.

13. Describe any implementation and/or operational challenges, including plans for and results of associated corrective actions. After the first quarter, only report on changes and/or updates, as appropriate. There were no notable implementation and/or operational challenges experienced in Q3.

MGARA has under consideration whether to convert its reinsurance program to a retropsective model as of 1/1/22.

MGARA is awaiting the Maine Bureau of Insurance decision regarding implementation of the small group market merger, which will require a ramp-up in effort to plan the implementation of that revised operating model beginning 1/1/23.

Section 1332 of the Patient Protection and Affordable Care Act (PPACA) State Innovation Waivers – Reinsurance Waiver Quarterly Report

D. POST-AWARD FORUM (for Quarter Post-Award Forum was held)						
14. Was the date, time, and location of the Post-Award Forum advertised 30 days in advance?						
(• Yes						
(No						
15. State website address where Post-Award Forum was advertised						
The notice was published on two websites: www.mgara.org and www.maine.gov/pfr/insurance/						
16. Date Post-Award Forum took place						
2021 Forum is to be held June 7, 2021 at 1 PM EST by Zoom meeting.						
17. Summary of Post-Award Forum, held in accordance with §155.1320(c), including all public comments received and actions taken in response to concerns or comments.						
The Summary of Post-Award Forum to be held June 7, 2021 will be provided with MGARA's Q2 report.						
18. Other Attachments (attach other documents as needed pertaining to Post-Award Form						
None						

MGARA Balance Sheet as of 3/31/2021

	2021	2020
Assets		
Cash/Investments (Note 1)	\$68,622,889	\$46,227,412
Assessment Receivable	68,532	-
Accrued Investment Interest Receivable	364,365	130,837
Allowance for Bad Debts		-
Premium Receivable	3,363,925	3,023,232
Grant Receivable	-	-
Claims Receivable	-	-
IBNR Premiums	1,900,000	400,000
Prepaid Expenses	0	0
Total Assets	\$74,319,711	\$49,781,480
Liabilities		
Accounts Payable (Note 2)	\$247,525	\$176,175
Claims Payable	7,579,419	6,395,513
IBNR Liability	15,000,000	14,900,000
Deferred Assessment Liability	-	0
Line of Credit		0
Total Liabilities	\$22,826,944	\$21,471,688
Fund Balance	\$51,492,767	\$28,309,792

Statement of Revenues and Expenditures

For the 3 Months Ending March 31, 2021

	Current Month	YTD 2021	YTD 2020	Full Year 2021 Projected*	2021 YTD % of Projected
Revenues					
Regular Assessment	\$0	\$0	\$253,548	\$25,000,000	0%
Additional Assessment	-	-	1-		
Premiums	3,177,680	9,392,207	9,266,674	31,300,000	30%
Grant Revenue (Note 4)	-	-	-	30,800,000	0%
Change in Premium IBNR	-	-	-		
Gain on Investments	(157,904)	(700,523)	(151,961)		
Interest Income	170,889	680,308	225,758		
Total Income	\$3,190,666	\$9,371,991	\$9,594,019	\$87,100,000	11%
Total Income excluding Assessments					
and Grants		\$9,371,991	\$9,340,471	\$31,300,000	30%
Expenditures					
Claims Incurred	\$5,190,481	\$13,570,026	\$10,845,725	\$86,000,000	16%
Change in IBNR	-	-	-		
Administration Fees	57,318	163,600	139,554	7	
Interest Expense	-		-		
Professional Fees (Note 3)	106,285	142,447	187,103	1,100,000	30%
Insurance Expense	18,958	18,958	-	1	
Bank Charges	919	1,486	2,543		
Other Expenses	-	-	-	_	
Total Expenses	\$5,373,961	\$13,896,517	\$11,174,925	\$87,100,000	16%
Revenues excluding Assessments and Grants					
in Excess of Expenditures	\$-2,183,295	\$-4,524,526	\$-1,834,454	\$-56,300,000	8%
Revenues in Excess of Expenditures/ (Expenditures in Excess of Revenues)	\$-2,183,295	\$-4,524,526	\$-1,580,906	\$0	#DIV/0!
Fund Balance - Beginning		\$56,017,294	\$29,890,698		
Fund Balance - Ending		\$51,492,768	\$28,309,792	\$0	